Epidemiological study of hospitalization associated with respiratory syncytial virus infection in Taiwanese children between 2004 and 2007.

BACKGROUND/PURPOSE Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in young children. The population-based burden of RSV hospitalization and the effect of potential risk factors on the severity of illness were evaluated in Taiwanese children. METHODS We analyzed the annual population-based incidence, underlying diseases and characteristics of hospitalizations due to RSV in Taiwanese children under 5 years of age from 2004 to 2007 by using Taiwan's National Health Insurance database. RESULTS A total of 11,081 children with RSV-associated hospitalization were studied. Average annual population-based hospitalization incidence was 1,077 and 232 per 100,000 children-year in children under 6 months and under 5 years of age, respectively. The peak incidence occurred between 1 and 2 months of age. The male-to-female incidence risk ratio was 1.4:1 (p < 0.001). There was a significant seasonal distribution with consistent peaks in the spring and autumn every year (p < 0.001). A total of 373 patients (3.3%) had repeated RSV infection. The 943 children (8.5%) with underlying diseases were older (p = 0.001), required longer intensive care unit (ICU) stays (p < 0.001), had a higher rate of endotracheal intubation (p < 0.05), and incurred higher medical costs (p < 0.001). A total of 888 patients (8%) required ICU care. Younger age (p < 0.001), prematurity (p < 0.001), cerebral palsy (p < 0.001) and congenital heart disease (p < 0.001) were independent predictors of requiring ICU care. CONCLUSION RSV infection occurs biennially with peaks in spring and fall in Taiwan. Patients with underlying diseases need longer hospital and ICU stays and incur higher medical costs. Younger age, prematurity, congenital heart disease and cerebral palsy are predictors of ICU care.

[1]  William A Prescott,et al.  Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis , 2012, PharmacoEconomics.

[2]  E. Simões,et al.  An update on respiratory syncytial virus epidemiology: a developed country perspective. , 2002, Respiratory medicine.

[3]  L. Lehtonen,et al.  Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis , 2004, Archives of Disease in Childhood - Fetal and Neonatal Edition.

[4]  C. Menéndez,et al.  Epidemiology and clinical presentation of respiratory syncytial virus infection in a rural area of southern Mozambique , 2002, The Pediatric infectious disease journal.

[5]  Kevin Purcell,et al.  Driscoll Children’s Hospital Respiratory Syncytial Virus Database: Risk Factors, Treatment and Hospital Course in 3308 Infants and Young Children, 1991 to 2002 , 2004, The Pediatric infectious disease journal.

[6]  C. Hall,et al.  Respiratory Syncytial Virus , 1983 .

[7]  L. Anderson,et al.  Annual Variation in Respiratory Syncytial Virus Season and Decisions Regarding Immunoprophylaxis With Palivizumab , 2004, Pediatrics.

[8]  Chin‐Yun Lee,et al.  Epidemiology of respiratory syncytial virus infection in northern Taiwan, 2001-2005 -- seasonality, clinical characteristics, and disease burden. , 2007, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[9]  E. Wang,et al.  Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. , 1995, The Journal of pediatrics.

[10]  M. Rennels,et al.  Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. , 2003, Pediatrics.

[11]  L. Krilov Respiratory syncytial virus: Update on infection, treatment, and prevention , 2001, Current infectious disease reports.

[12]  Carlo Chezzi,et al.  Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics , 2007, European Journal of Pediatrics.

[13]  L. Weisman Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions , 2003, The Pediatric infectious disease journal.

[14]  Ian Mitchell,et al.  The Pediatric Investigators Collaborative Network on Infections in Canada Study of Predictors of Hospitalization for Respiratory Syncytial Virus Infection for Infants Born at 33 Through 35 Completed Weeks of Gestation , 2004, The Pediatric infectious disease journal.

[15]  G. Zuccotti,et al.  Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity , 2002, Pediatric pulmonology.

[16]  J. Devasundaram,et al.  Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus , 2003, The Pediatric infectious disease journal.

[17]  L. Weckx,et al.  Optimization strategy to minimize wastage of palivizumab during the 2008 RSV season in São Paulo, Brazil. , 2009, Journal of Tropical Pediatrics.

[18]  José Quero,et al.  Case-Control Study of the Risk Factors Linked to Respiratory Syncytial Virus Infection Requiring Hospitalization in Premature Infants Born at a Gestational Age of 33–35 Weeks in Spain , 2004, The Pediatric infectious disease journal.

[19]  C B Hall,et al.  R ESPIRATORY S YNCYTIAL V IRUS AND P ARAINFLUENZA V IRUS , 2001 .

[20]  Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. , 1998, Pediatrics.

[21]  H. Dorkin,et al.  Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. , 1999, The Pediatric infectious disease journal.

[22]  E. Simões Respiratory syncytial virus infection , 1999, The Lancet.

[23]  K. Cann Principles and practice of infectious disease , 1990 .

[24]  C. Meissner,et al.  Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease , 2004 .

[25]  M. E. Ryan,et al.  RSV infection in infants and young children. What's new in diagnosis, treatment, and prevention? , 1999, Postgraduate medicine.

[26]  E. Simões Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. , 2003, The Journal of pediatrics.

[27]  S. Khatijah,et al.  Risk factors for hypoxemia and respiratory failure in respiratory syncytial virus bronchiolitis. , 2002, The Southeast Asian journal of tropical medicine and public health.

[28]  J. Friedland,et al.  Basic epidemiology and immunopathology of RSV in children. , 2000, Paediatric respiratory reviews.

[29]  M. Jeng,et al.  Epidemiology of respiratory syncytial virus in children with lower respiratory tract infection. , 2005, Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi.

[30]  Jen-Ren Wang,et al.  Respiratory Viral Infections among Pediatric Inpatients and Outpatients in Taiwan from 1997 to 1999 , 2001, Journal of Clinical Microbiology.

[31]  W. Gilbert,et al.  Cost, causes and rates of rehospitalization of preterm infants , 2007, Journal of Perinatology.

[32]  P. Stang,et al.  Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. , 2000, The Journal of pediatrics.

[33]  W. P. Glezen,et al.  Risk of primary infection and reinfection with respiratory syncytial virus. , 1986, American journal of diseases of children.

[34]  J. Sinnott,et al.  Respiratory Syncytial Virus , 1988, Infection Control & Hospital Epidemiology.

[35]  D. J. Burch,et al.  International variation in the management of infants hospitalized with respiratory syncytial virus , 1998, European Journal of Pediatrics.

[36]  A. Randolph,et al.  Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. , 2004, The Cochrane database of systematic reviews.

[37]  P. Cane,et al.  Incidence and severity of respiratory syncytial virus pneumonia in rural Kenyan children identified through hospital surveillance. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  K. Poehling,et al.  The burden of respiratory syncytial virus infection in young children. , 2009, The New England journal of medicine.